Cytomegalovirus Prophylaxis versus Pre-emptive Strategy: Different CD4
CMV
Immune recovery
Pre-emptive therapy
Prophylaxis treatment
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
30
10
2020
revised:
05
02
2021
accepted:
01
03
2021
pubmed:
5
4
2021
medline:
3
7
2021
entrez:
4
4
2021
Statut:
ppublish
Résumé
Reconstitution of T cells after transplantation is a determinant of the long-term success of the procedure, and the correlation with T cell recovery and cytomegalovirus reactivation and disease is well known. We evaluated 110 patients who underwent transplantation: 55 received pre-emptive antiviral treatment, and in the other 55 patients, prophylaxis with letermovir was employed. A progressive statistically significant difference in T cell reconstitution between the 2 groups was observed, starting from day +60 with faster recovery in the pre-emptive group. Moreover, a higher incidence of cytomegalovirus reactivation was observed in prophylactic group after discontinuation of letermovir, and subsequent antiviral treatment has been necessary. Our findings confirm, as previously reported, that cytomegalovirus reactivation is a potent stimulator of T cell function.
Identifiants
pubmed: 33812803
pii: S2666-6367(21)00746-6
doi: 10.1016/j.jtct.2021.03.003
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
518.e1-518.e4Informations de copyright
Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.